Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan
Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan.
Europace. 2015 Aug;17(8):1309-15. doi: 10.1093/europace/euu335. Epub 2015 Jan 6.
Photodynamic therapy (PDT) is based on non-thermal injury mediated by singlet oxygen species and is used clinically in cancer therapy. In our continuing efforts to apply this technology to cardiac catheter ablation, we clarified the optimal condition for creating PDT-mediated lesions using a laser catheter.
In a total of 35 canines, we applied a laser directly to the epicardium of the beating heart during open-chest surgery at 15 min after administration of a photosensitizer, talaporfin sodium. We evaluated the lesion size (depth and width) using hematoxylin-eosin staining under varying conditions as follows: laser output (5, 10, 20 W/cm(2)), irradiation time (0-60 s), photosensitizer concentration (0, 2.5, 5 mg/kg), blood oxygen concentration (103.5 ± 2.1 vs. 548.0 ± 18.4 torr), and contact force applied during irradiations (low: <20 g, high: >20 g). A laser irradiation at 20 W/cm(2) for 60 s under 5 mg/kg (29 µg/mL) of photosensitizer induced a lesion 8.7 ± 0.8 mm deep and 5.2 ± 0.2 mm wide. The lesion size was thus positively correlated to the laser power, irradiation time, and photosensitizer concentration, and was independent of the applied contact force and oxygen concentration. In addition, the concentration of the photosensitizer strongly correlated with the changes in the pulse oximetry data and fluorescence of the backscattering laser, suggesting that a clinically appropriate condition could be estimated in real time.
Photodynamic therapy-mediated cardiac lesions might be controllable by regulating the photosensitizer concentration, laser output, and irradiation time.
光动力疗法(PDT)基于单线态氧物质介导的非热损伤,临床上用于癌症治疗。在我们不断努力将这项技术应用于心脏导管消融术的过程中,我们使用激光导管阐明了创建 PDT 介导损伤的最佳条件。
在总共 35 只犬中,我们在开胸手术中于给予光敏剂他拉泊芬钠后 15 分钟,直接将激光应用于跳动心脏的心外膜。我们通过以下不同条件评估了病变大小(深度和宽度):激光输出(5、10、20 W/cm(2))、照射时间(0-60 s)、光敏剂浓度(0、2.5、5 mg/kg)、血氧浓度(103.5 ± 2.1 与 548.0 ± 18.4 托)和照射时施加的接触力(低:<20 g,高:>20 g)。在 5 mg/kg(29 µg/mL)的光敏剂下,以 20 W/cm(2)的激光照射 60 s 可诱导 8.7 ± 0.8 mm 深和 5.2 ± 0.2 mm 宽的病变。病变大小与激光功率、照射时间和光敏剂浓度呈正相关,与施加的接触力和氧浓度无关。此外,光敏剂的浓度与脉搏血氧仪数据的变化和背散射激光的荧光强烈相关,表明可以实时估计临床合适的条件。
通过调节光敏剂浓度、激光输出和照射时间,可以控制光动力疗法介导的心脏损伤。